GlyTR Therapeutics
PrivateLast Round
Grant
Sep 10, 2025
Total Funding Raised
$8.65M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
GlyTR Therapeutics is a biotechnology company developing a new class of anti-cancer immunotherapeutic molecules and CAR-T cells.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GlyTR Therapeutics Comparables
Compare GlyTR Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GO Therapeutics | 83% | |
| Tacalyx | 79% | |
| Saccharo | 79% |
GlyTR Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 10, 2025 | ||||
| Grant | Feb 21, 2025 | ||||
| Grant | Oct 10, 2023 | ||||
| Series A | Oct 22, 2018 | ||||
| Grant | Sep 18, 2018 | ||||
Accelerator | May 17, 2016 |
Key People
Founding team and executive leadership
GlyTR Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| NIH RADx | Grant |
| EvoNexus | Accelerator |
| California Institute for Regenerative Medicine | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 388% MoM, reaching 1.1K.
- Sep 10, 2025
$464K grant round completed.
GlyTR Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about GlyTR Therapeutics's valuation, stock price, and market status.
Is GlyTR Therapeutics a public or private company?
GlyTR Therapeutics is a private company.
What is the current stock price of GlyTR Therapeutics?
GlyTR Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is GlyTR Therapeutics worth (valuation)?
Valuation information for GlyTR Therapeutics is not publicly available.
Can I buy GlyTR Therapeutics stock?
GlyTR Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was GlyTR Therapeutics's last funding round?
GlyTR Therapeutics's most recent funding round was Grant on September 10, 2025.
Who are the main investors in GlyTR Therapeutics?
Key investors in GlyTR Therapeutics include EvoNexus.
Will GlyTR Therapeutics IPO soon?
No public IPO plans have been announced for GlyTR Therapeutics.
How can I track GlyTR Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor GlyTR Therapeutics's secondary market activity and sign up for updates.